Nov 10, 2022 | News, Press Release
FOR IMMEDIATE RELEASE November 10, 2022- The Alpha-1 Foundation announces the appointment of Andrew A. Wilson, MD as its new Scientific Director. Dr. Wilson assumes this role with a long-standing passion and commitment to the Alpha-1 community. “On behalf of the...
Apr 1, 2022 | News, Press Release
FOR IMMEDIATE RELEASE –Today, April 1, 2022, H.R. 7346: John W. Walsh Home Infusion Act will be introduced. This legislation, when passed, will change the Medicare law to improve access to augmentation therapy infusions at home for individuals with Alpha-1 Antitrypsin...
Oct 14, 2021 | News, Press Release
“The update shared this week by Inhibrx on their Recombinant Alpha-1-antitrypsin (INBRX-101) is exciting news for the Alpha-1 Community. The potential for a once a month dosing of Alpha-1-antitrypsin could be a very important advance in therapies for...
Oct 8, 2021 | News, Press Release
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “The Alpha-1 Foundation is committed to provide...
Sep 30, 2021 | News, Press Release
FOR IMMEDIATE RELEASE The Alpha-1 Foundation announces the selection of Mr. Scott Santarella as the new President and Chief Executive Officer (CEO). Scott joins us with extensive experience in building and transforming disease-focused non-profits and a strong passion...
Aug 20, 2021 | News, Press Release
A company that profits from the sale of tobacco products that cause COPD should not profit from the sale of products that treat COPD Washington, D.C., July 29, 2021 – Philip Morris International, which markets cigarettes internationally, is purchasing the...
